Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM. Abnormal placental growth factor and the risk of adverse neonatal and maternal outcomes. Obstet Gynecol 2020;135.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 1 of 4
Appendix 1. PETRA Investigators and Affiliations Principal Investigator Institution
R.H. Ball Maternal Fetal Services of Utah, Salt Lake City, UT J.R. Barton Baptist Health Lexington, Lexington, KY
R. Beyerlein Clinical Trials of America, Inc., Eugene, OR K.A. Boggess University of North Carolina, Chapel Hill, NC C.A.Combs Obstetrix Medical Group, San Jose, CA
L. A. Friel University of Texas Health Sciences Center, Houston, TX C. Gyamfi-Bannerman Columbia University Medical Center, New York, NY H.Y. How Norton Healthcare, Louisville, KY
S. Joy Carolinas HealthCare System, Charlotte, NC A. Lee Corvallis Clinic, Corvallis, OR
B.J. Levine Phoenix OB/GYN, Moorestown, NJ
D.F. Lewis Jr Greater Cincinnati OB/GYN, Inc., Cincinnati, OH J.N. Martin Jr University of Mississippi, Jackson, MS
A.L. Ness Saint Peter's University Hospital, New Brunswick, NJ L. Pereira Oregon Health & Science University, Portland, OR R.R. Reagan Women’s Healthcare, San Diego, CA
C.J. Robinson Medical University of South Carolina, Charleston, SC S. Sadanandan Regional Obstetrical Consultants, Chattanooga, TN C. Saffer West Coast OB/GYN, San Diego, CA
S. Sunderji ProMedica Physician Group,Toledo, OH F. Tillman Discovery Clinical Trials, Dallas, TX
P. von Dadelszen BC Women’s Hospital and Health Centre, Vancouver, BC, Canada
Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM. Abnormal placental growth factor and the risk of adverse neonatal and maternal outcomes.
Obstet Gynecol 2020;135.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 2 of 4
Appendix 2. Hypertensive Disorder Categories by Placental Growth Factor Level
Diagnosis All PlGF Category P
Low PlGF n=1112 ≤100 (n=742) >100 (n=370)
Preeclampsia with severe features* 684 (61.5) 525 (70.8) 159 (43.0) <0.001
Preeclampsia without severe features or gestational hypertension 168 (15.1) 104 (14.0) 64 (17.3)
Chronic hypertension† 70 (6.3) 32 (4.3) 38 (10.3)
No hypertensive disorder 190 (7.1) 81 (10.9) 109 (29.5)
Very low PlGF n=1112 <12 (n=353) ≥12 (n=759)
Preeclampsia with severe features* 684 (61.5) 298 (84.4) 386 (50.9) <0.001
Preeclampsia without severe features or gestational hypertension 168 (15.1) 23 (6.5) 145 (19.1)
Chronic hypertension† 70 (6.3) 7 (2.0) 63 (8.3)
No hypertensive disorder 190 (7.1) 25 (7.1) 165 (21.7)
PlGF, placental growth factor.
Data are presented as n (%).
*Includes gestational hypertension with severe range blood pressure and superimposed preeclampsia.
†Chronic hypertension without evidence of preeclampsia.
Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM. Abnormal placental growth factor and the risk of adverse neonatal and maternal outcomes.
Obstet Gynecol 2020;135.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 3 of 4
Appendix 3. Composite Neonatal Adverse Outcome by Hypertensive Disorder Categories, Placental Growth Factor, and Small for Gestational Age
Low PlGF
Hypertensive Disorder Diagnosis* All Outcome ≤100 Outcome >100 Outcome
Overall 1105 71 (6.4) 737 68 (9.2) 368 3 (0.8)
No SGA 776 30 (3.9) 454 27 (5.9) 322 3 (0.9)
SGA 329 41 (12.5) 283 41 (14.5) 46 0 (0.0)
Preeclampsia with severe features† 682 61 (8.9) 523 59 (11.3) 159 2 (1.3)
No SGA 434 24 (5.5) 298 22 (7.4) 136 2 (1.5)
SGA 248 37 (14.9) 225 37 (16.4) 23 0 (0.0)
Preeclampsia without severe features‡ 168 1 (0.6) 104 1 (1.0) 64 0 (0.0)
No SGA 134 0 (0.0) 76 0 (0.0) 58 0 (0.0)
SGA 34 1 (2.9) 28 1 (3.6) 6 0 (0.0)
Chronic hypertension§ 68 2 (2.9) 31 2 (6.5) 37 0 (0.0)
No SGA 52 0 (0.0) 21 0 (0.0) 31 0 (0.0)
SGA 16 2 (12.5) 10 2 (20.0) 6 0 (0.0)
No hypertensive disorder 187 7 (3.7) 79 6 (7.6) 108 1 (0.9)
No SGA 156 6 (3.8) 59 5 (8.5) 97 1 (1.0)
SGA 31 1 (3.2) 20 1 (5.0) 11 0 (0.0)
Very low PlGF
Hypertensive Disorder Diagnosis* All Outcome <12 Outcome ≥12 Outcome
Overall 1105 71 (6.4) 351 58 (16.5) 754 13 (1.7)
No SGA 776 30 (3.9) 172 22 (12.8) 604 8 (1.3)
SGA 329 41 (12.5) 179 36 (20.1) 150 5 (3.3)
Preeclampsia with severe features† 682 61 (8.9) 296 50 (16.9) 386 11 (2.8)
No SGA 434 24 (5.5) 142 18 (12.7) 292 6 (2.1)
SGA 248 37 (14.9) 154 32 (20.8) 94 5 (5.3)
Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM. Abnormal placental growth factor and the risk of adverse neonatal and maternal outcomes.
Obstet Gynecol 2020;135.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 4 of 4
Preeclampsia without severe features‡ 168 1 (0.6) 23 1 (4.3) 145 0 (0.0)
No SGA 134 0 (0.0) 10 0 (0.0) 124 0 (0.0)
SGA 34 1 (2.9) 13 1 (7.7) 21 0 (0.0)
Chronic hypertension§ 68 2 (2.9) 7 2 (28.6) 61 0 (0.0)
No SGA 52 0 (0.0) 4 0 (0.0) 48 0 (0.0)
SGA 16 2 (12.5) 3 2 (66.7) 13 0 (0.0)
No hypertensive disorder 187 7 (3.7) 25 5 (20.0) 162 2 (1.2)
No SGA 156 6 (3.8) 16 4 (25.0) 140 2 (1.4)
SGA 31 1 (3.2) 9 1 (11.1) 22 0 (0.0)
PlGF, placental growth factor; SGA, small for gestational age.
Data are presented as n or n (%).
*Adjudicated diagnoses reclassified into ACOG 2019 Practice Bulletin categories.
†Includes gestational hypertension with severe range blood pressure and superimposed preeclampsia.
‡Includes gestational hypertension with mild range blood pressure.
§Chronic hypertension without evidence of preeclampsia.
